Irinotecan Ever Pharma

Irinotecan, the active ingredient in Irinotecan Ever Pharma, is a Topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in oncology to treat certain colorectal cancers in adult patients, often as part of combination chemotherapy regimens.

GNH USA supplies Irinotecan Ever Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotecan is used in oncology to target cancers that respond to topoisomerase I inhibition.

- Metastatic colorectal cancer: improves overall survival when combined with fluorouracil and leucovorin. - Adjuvant colorectal cancer: reduces risk of disease recurrence after surgical resection. - Advanced colorectal cancer (refractory): provides disease control in patients who have progressed on prior therapies.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: may be managed with antiemetics. - Alopecia: temporary hair loss. - Fatigue: general tiredness during treatment. - Abdominal cramping: discomfort in the stomach area.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis: inflammation of the colon that can be life‑threatening. - Hepatotoxicity: liver enzyme elevations indicating liver injury. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Hemorrhagic cystitis: bladder inflammation with bleeding. - Cardiotoxicity: rare heart rhythm disturbances.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor laboratory parameters closely.

- Baseline blood counts: obtain CBC to detect pre‑existing neutropenia. - Liver function: evaluate hepatic enzymes as irinotecan is metabolized hepatically. - Renal function: adjust dosing in patients with impaired clearance. - Concomitant medications: avoid drugs that strongly inhibit UGT1A1, which may increase SN‑38 exposure. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with obstetric specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan interacts with several agents that can alter its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong UGT1A1 inhibitors (e.g., atazanavir): may raise SN‑38 levels and risk severe neutropenia. - CYP3A4 inducers (e.g., rifampin): can reduce efficacy by increasing drug clearance.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR as irinotecan may affect clotting parameters. - Other myelosuppressive agents: increase risk of profound bone‑marrow suppression. - Antidiarrheal agents (e.g., loperamide): use cautiously to avoid masking severe diarrhea. - Proton pump inhibitors: may affect gastric pH and drug absorption modestly.